Our analysis of data from multiple large, randomized studies is reassuring and does not demonstrate an excess risk of neurocognitive disorders, cancer, cataract, hepatobiliary disorders, muscle disorders, diabetes, and adverse events leading to drug discontinuation in patients treated with PCSK9 inhibitors on a background of statin therapy who achieve very low LDL-C levels. This evidence concerns the gene PCSK9 and muscular disease.